Recon: Moderna announces more than $6B in revenue in first quarter; Valneva to trial booster of its COVID vaccine
ReconJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy